Key Takeaways
- • Frazier Healthcare Partners has taken a majority stake in Atum, a bioengineering company based in Newark, California, according to PEI Private Equity.
- • Atum combines machine learning, gene synthesis and cell line development to help biopharma companies advance new therapies toward the clinic.
- • The source article does not disclose the transaction value or the stake size beyond the term "majority."
Summary
Atum's platform integrates machine learning, gene synthesis and cell line development. The company positions these capabilities as tools that help biopharmaceutical companies move new therapies into clinical development. The reported coverage does not specify the purchase price, the exact ownership percentage, or the remaining stakeholders.
For institutional allocators and private equity professionals, the deal reflects continued interest in technology-enabled enabling platforms serving drug developers. Further detail on terms, valuation and post-deal strategy would be needed from the transaction announcement or filings.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.